Rahil Mashhadi1, Gholamreza Pourmand2, Farid Kosari3, Abdolrasoul Mehrsai4, Sepehr Salem4, Mohammad Reza Pourmand5, Sudabeh Alatab4, Mehdi Khonsari4, Fariba Heydari4, Laleh Beladi4, Farimah Alizadeh4. 1. Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran. rh_mashhadi@yahoo.com. 2. Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran. gh_pourman@yahoo.com. 3. Department of Pathology, Sina Hospital, Tehran University of Medical Science, Tehran, Iran. 4. Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran. 5. Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Abstract
PURPOSE: To compare the expression rate of sex steroid hormone receptors of estrogen (ER), progesterone (PR) and androgen (AR) in normal urothelium and urothelial bladder cancer (UBC) and to evaluate the possible associations of these receptors expression with cancer progression and patient's survival. MATERIALS AND METHODS: We evaluated the clinical data and tumor specimens of 120 patients with pathologically confirmed primary UBC with 132 normal healthy controls. Both patients and controls selected from list of subjects who have been referred to Sina Urology clinic, and had a minimum of one year follow-up duration. Data collected from medical cords. For evaluation of expression, immunohistochemistry was performed on paraffin-embedded tissue sections using a monoclonal antibody for androgen, estrogen and progesterone receptors. Presence of at least 10% positive cells defined as positive expression. RESULTS: None of the control subjects showed AR expression, while 22% of the patients were AR-positive. ER/PR expressions were observed in 4.2%/ and 2.5% of the cases and in 2.3% and 1.5% of the controls, respectively. A statistically significant correlation was found between AR expression and tumor stage and grade (P < .001). AR-positive patients showed a significantly poorer prognosis than AR-negative cases (log-rank test, P = .02, hazard ratio = 2.12; 95% confidence interval: 1.36-4.65). CONCLUSION: AR expression was significantly associated with higher grade and poorly differentiated tumors with unfavorable outcome. AR expression test might be useful as a diagnostic tool for determining the malignancy and outcome of UBC patients.
PURPOSE: To compare the expression rate of sex steroid hormone receptors of estrogen (ER), progesterone (PR) and androgen (AR) in normal urothelium and urothelial bladder cancer (UBC) and to evaluate the possible associations of these receptors expression with cancer progression and patient's survival. MATERIALS AND METHODS: We evaluated the clinical data and tumor specimens of 120 patients with pathologically confirmed primary UBC with 132 normal healthy controls. Both patients and controls selected from list of subjects who have been referred to Sina Urology clinic, and had a minimum of one year follow-up duration. Data collected from medical cords. For evaluation of expression, immunohistochemistry was performed on paraffin-embedded tissue sections using a monoclonal antibody for androgen, estrogen and progesterone receptors. Presence of at least 10% positive cells defined as positive expression. RESULTS: None of the control subjects showed AR expression, while 22% of the patients were AR-positive. ER/PR expressions were observed in 4.2%/ and 2.5% of the cases and in 2.3% and 1.5% of the controls, respectively. A statistically significant correlation was found between AR expression and tumor stage and grade (P &lt; .001). AR-positive patients showed a significantly poorer prognosis than AR-negative cases (log-rank test, P = .02, hazard ratio = 2.12; 95% confidence interval: 1.36-4.65). CONCLUSION: AR expression was significantly associated with higher grade and poorly differentiated tumors with unfavorable outcome. AR expression test might be useful as a diagnostic tool for determining the malignancy and outcome of UBCpatients.&nbsp;
Authors: Francesca Sanguedolce; Luigi Cormio; Giuseppe Carrieri; Beppe Calò; Davide Russo; Andrea Menin; Antonio Luigi Pastore; Francesco Greco; Giorgio Bozzini; Antonio Galfano; Giovannalberto Pini; Angelo Porreca; Filippo Mugavero; Mario Falsaperla; Carlo Ceruti; Luca Cindolo; Alessandro Antonelli; Andrea Minervini Journal: Histol Histopathol Date: 2019-12-05 Impact factor: 2.303
Authors: Marco Moschini; Emanuele Zaffuto; Pierre Karakiewicz; Agostino Mattei; Giorgio Gandaglia; Nicola Fossati; Francesco Montorsi; Alberto Briganti; Shahrokh F Shariat Journal: World J Urol Date: 2018-10-01 Impact factor: 4.226